Indeed, CD123 expression has been demonstrated on neoplastic cells in blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), acute lymphoblastic leukemia/lymphoma (ALL), hairy cell leukemia (HCL), systemic mastocytosis (SM), etc. [1,5]. This evidence concerns the gene IL3RA and CD4+/CD56+ hematodermic neoplasm.